SCB-2019 | Wikipedia Easy Search

SCB-2019
Vaccine description
Target	SARS-CoV-2
Vaccine type	Protein subunit
Clinical data
Routes of administration	Intramuscular
Identifiers
DrugBank	DB15805

COVID-19 pandemic
Part of a series on the
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023 2024
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health symptoms Migration Military Notable deaths Other health issues Politics diplomacy Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Society Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies.^[1] Positive results of Phase I trials for the vaccine were published in The Lancet^[2] and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021.^[3] In September 2021, SCB-2019 announced Phase III results showing 67% efficacy against all cases of COVID-19 and 79% efficacy against all cases of the Delta variant. Additionally, the vaccine was 84% effective against moderate cases and 100% effective against hospitalization.^[4]

SCB-2019 is being funded by CEPI as part of COVAX^[5] and has received advanced purchase orders from GAVI for 400 million doses,^[6] with production to begin in 2021.^[7]

^ "Chinese biotech firm Clover signs deal to make millions of vaccines". South China Morning Post. 30 June 2021. Retrieved 8 July 2021.
^ Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, et al. (February 2021). "Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial". Lancet. 397 (10275): 682–694. doi:10.1016/S0140-6736(21)00241-5. PMC 7906655. PMID 33524311.
^ Cite error: The named reference :2 was invoked but never defined (see the help page).
^ Liu R (22 September 2021). "Clover's vaccine 67% effective against COVID, 79% against Delta variant in large trial". Reuters. Retrieved 22 September 2021.
^ Rogers J (July 2021). "From lab to potential jab: Clover's COVID-19 vaccine story". CEPI. Retrieved 8 July 2021.
^ "Gavi signs agreement with Clover Biopharmaceuticals for supply to COVAX". www.gavi.org. Retrieved 8 July 2021.
^ "Clover's COVID-19 shot tames delta in pivotal study, delivering boost to global vaccination campaign". FierceBiotech. 22 September 2021. Retrieved 22 September 2021.